SCHEMBL6074023

SCHEMBL6074023

C[C@@H]1CN(c2ccc(Nc3ncc4ccc(NC(=O)NC5CCCCC5)nc4n3)cc2)C[C@H](C)N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 8/20 0.49
CCND1 P24385 6/20 0.49
CCNA2 P20248 2/20 0.49
CDK2 P24941 2/20 0.49
FGFR1 P11362 2/20 0.49
FGFR2 P21802 2/20 0.49
FGFR4 P22455 2/20 0.49
FGFR3 P22607 2/20 0.49
CCNT1 O60563 1/20 0.49
CDK9 P50750 1/20 0.49
CCND2 P30279 3/20 0.47
CCND3 P30281 3/20 0.47
AURKB Q96GD4 1/20 0.46
CDK6 Q00534 2/20 0.44
CSF1R P07333 1/20 0.44
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
JAK3 P52333 1/20 0.43
SYK P43405 5/20 0.42
HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6074026 1.00 CDK4 (0.49) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6074226 0.86 CDK4 (0.54) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6073955 0.86 CDK4 (0.51) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6074286 0.86 CDK4 (0.47) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6073951 0.86 CDK4 (0.51) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6074297 0.86 CDK4 (0.47) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6073608 0.85 CDK4 (0.48) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6073614 0.85 CDK4 (0.48) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6073815 0.85 CDK4 (0.45) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL6073811 0.85 CDK4 (0.45) CDK4CCND1CCNA2CDK2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP claimed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CCNA2 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.